论文部分内容阅读
目的:评价吲哚美辛联合重组牛碱性成纤维细胞生长因子治疗持续性角膜上皮缺损(persistent corneal epithelial defects,PCED)的临床疗效。方法:将48例(48眼)PCED患者随机分成治疗组(24例)和对照组(24例),治疗组应用吲哚美辛滴眼液和重组牛碱性成纤维细胞生长因子滴眼液滴眼,对照组单用重组牛碱性成纤维细胞生长因子滴眼液滴眼。上述2药的用法均为每日滴眼4次,每次1～2滴,疗程2周。比较2组疗效。结果:治疗组总有效率为88%,对照组相应为62%,2组总有效率比较差异有统计学意义(P(0.05);2组治疗期间未出现眼部刺激症状和全身不良反应。结论:吲哚美辛联合重组牛碱性成纤维细胞生长因子治疗PCED疗效确切,可供临床酌情选用。
Objective: To evaluate the clinical efficacy of indometacin combined with recombinant bovine basic fibroblast growth factor in the treatment of persistent corneal epithelial defects (PCED). Methods: 48 patients (48 eyes) with PCED were randomly divided into treatment group (24 cases) and control group (24 cases). The treatment group was treated with indomethacin eye drops and recombinant bovine basic fibroblast growth factor eye drops Eye drops, the control group with recombinant bovine basic fibroblast growth factor eye drops. The usage of the above two drugs are eye drops 4 times a day, each 1 to 2 drops, treatment for 2 weeks. Compare 2 groups curative effect. Results: The total effective rate was 88% in the treatment group and 62% in the control group. The total effective rate in the two groups was statistically significant (P <0.05). No eye irritation symptoms and systemic adverse reactions occurred in the two groups. Conclusion: Indomethacin combined with recombinant bovine basic fibroblast growth factor for the treatment of PCED is effective and can be used clinically.